Cardiovascular Systems Signs U.S. Distribution Agreement with Asahi Intecc Co., Ltd.
August 27 2009 - 3:03PM
Business Wire
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical
device company developing and commercializing innovative
interventional treatment systems for vascular disease, has signed
an exclusive distribution agreement with Asahi Intecc Co., Ltd.,
based in Japan, to market its peripheral guide wire line in the
United States.
“The addition of Asahi guide wires expands our product portfolio
and reinforces our leadership position in the peripheral arterial
disease or PAD market,” said David L. Martin, CSI president and
chief executive officer. “Asahi peripheral guide wires address
long, complex lesions above or below the knee, and complement the
plaque removal capabilities of our Diamondback 360°. This agreement
supports our mission to provide the more than 5,000 physicians and
2,000 hospitals treating PAD with comprehensive endovascular tools.
In just a few minutes of treatment time the Diamondback 360° can
keep patients walking and helps patients and their families avoid
the high economic costs and trauma related to immobility and
amputation.”
CSI’s flagship product is the Diamondback 360o® Peripheral
Arterial Disease System, a minimally invasive catheter system for
treating PAD. Between 8 million and 12 million Americans suffer
from PAD, which is caused by the accumulation of plaque in leg or
foot arteries, reducing blood flow. Symptoms include leg pain when
walking or at rest, and PAD can lead to tissue loss and eventually
limb amputation. The Diamondback 360o removes calcified and fibrous
plaque and restores blood flow in vessels both below and above the
knee.
“We are excited about the opportunity to work with CSI and its
sales and marketing organization,” said Masahiko Miayata, president
and chief executive officer of Asahi Intecc. “CSI is rapidly
building a loyal customer base of physicians focused on treating
PAD. We share the mutual goal of developing innovative technologies
with the capabilities to address difficult PAD cases and improve
patients’ lives.”
CSI will offer two Asahi 0.18 wire platforms: the Astato 30 and
Treasure 12. The Astato 30 is a high-penetration guide wire
specially designed to break through fibrous caps and calcium
deposits, and treat long, complex lesions. The Treasure 12 has a
one-piece core which provides exceptional control, superior torque
performance and tactile feedback to the physician.
Jihad Mustapha, M.D., Metro Health Hospital, Grand Rapids,
Mich., added, “I have used the Asahi wire in tough cases where
other technologies failed. Asahi provides wires with a unique
ability to transmit force applied outside of the body to the tip of
the wire. When rotated, the Asahi Wires seem to turn at a 1:1
ratio; that is, they behave in a controllable way, giving me the
ability to easily pass through the hard cap of a lesion. There is
nothing else like these wires on the market.”
In addition to the Diamondback 360°, CSI offers a portfolio of
supplemental PAD products, including its own Viper line. All
products are available through the CSI national sales
organization.
For additional information about Asahi Intecc Co., Ltd., visit
the company’s Web site at: http://www.asahi-intecc.com
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a
medical device company focused on developing and commercializing
interventional treatment systems for vascular disease. The
company’s Diamondback 360°® Peripheral Arterial Disease System
treats calcified and fibrotic plaque in small and large vessels,
and addresses many of the limitations associated with existing
surgical, catheter and pharmacological treatment alternatives. In
August 2007, the U.S. FDA granted 510(k) clearance for the use of
the Diamondback 360° as a therapy for PAD (peripheral arterial
disease), and CSI commenced a U.S. product launch in September
2007. Since then, almost 600 hospitals across the United States
have adopted the system, and more than 15,000 patients have been
treated. For more information visit the company’s Web site at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From May 2024 to Jun 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2023 to Jun 2024